))
How the “OpenAI of stem cell therapy” attracts partners without marketing
Manage episode 448906258 series 3612848
Contenu fourni par Joachim Eeckhout. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Joachim Eeckhout ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Micha Breakstone, CEO of Somite.ai, discusses how a single article in Forbes helped Somite to raise $5 million without having to chase investors, why branding Somite as a TechBio, rather than a Biotech, has helped to reduce the perceived risk for investors, and why early-stage science companies should focus their marketing efforts on specific objectives, like securing funding, attracting talent, or establishing partnerships.
In this episode, you'll learn:
02:13 The vision behind Somite.ai
04:18 Timing and strategy for launching Somite.ai
06:45 TechBio vs. Biotech: Understanding the difference
08:59 Partnership models in AI and Biotech
09:58 Creating a digital twin of a human embryo
12:00 Communication strategies for investors
14:09 Leveraging your scientific founders
16:27 Navigating the biotech landscape
17:58 Marketing strategies in science
20:38 Operational excellence and strategy
23:23 Commercialization models in TechBio
23:46 Marketing advice for science startups
26:03 Book recommendations for science communicators
Notes and references:
- The article from Forbes: This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market
- Book recommendation: The Song of the Cell by Siddhartha Mukherjee
To connect with Micha Breakstone:
- LinkedIn
To connect with Joachim Eeckhout, host of the podcast:
- LinkedIn
- Contact form
>>> Subscribe to The Science Marketer newsletter <<<
2 episodes
Partager
